Nivolumab-induced severe acute kidney injury with a long latent phase in a patient with non-small-cell lung cancer: A case report.

In the treatment of immunotherapy with immune checkpoint inhibitors, we often experience immune-related adverse event which manifest most frequently as a skin disorder, and very rarely as a renal disorder. In our manuscript, we report the case of a 71-year-old man with nivolumab-induced severe acute kidney injury (AKI) in which the time from treatment initiation to the onset of AKI was the longest among the previously reported cases (377 days). Prolonged follow-up is therefore warranted to detect late-onset AKI.